ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
102,544.75
-1.06%
S&P 500
6,086.37
0.61%
Dow Jones
44,156.73
0.30%
US Dollar vs Yen
156.7255
0.18%
Brent Oil
78.105
-0.29%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Kronos Bio Inc (KRON)

  7. Kronos Bio Inc (KRON) ニュース

KRON

Kronos Bio (KRON)

Kronos Bio Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:KRON
日付受信時刻ニュースソース見出しコード企業名
2024/11/2723 : 25AllPennyStocks.comCalifornia Biotech Stock Bid Up Prior To Opening Bell On Major AnnouncementNASDAQ:KRONKronos Bio Inc
2024/11/2721 : 30GlobeNewswire Inc.Kronos Bio Announces CEO Transition and Reduction in ForceNASDAQ:KRONKronos Bio Inc
2024/11/1514 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KRONKronos Bio Inc
2024/11/1506 : 02GlobeNewswire Inc.Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024NASDAQ:KRONKronos Bio Inc
2024/11/1406 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
2024/11/1406 : 05GlobeNewswire Inc.Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic AlternativesNASDAQ:KRONKronos Bio Inc
2024/11/0806 : 47Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KRONKronos Bio Inc
2024/11/0523 : 00GlobeNewswire Inc.Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple MyelomaNASDAQ:KRONKronos Bio Inc
2024/10/2321 : 55GlobeNewswire Inc.Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven TumorsNASDAQ:KRONKronos Bio Inc
2024/10/1607 : 57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
2024/10/1607 : 55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
2024/10/0921 : 55GlobeNewswire Inc.Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven TumorsNASDAQ:KRONKronos Bio Inc
2024/10/0721 : 55GlobeNewswire Inc.Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s DiseaseNASDAQ:KRONKronos Bio Inc
2024/09/2521 : 55GlobeNewswire Inc.Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory TherapyNASDAQ:KRONKronos Bio Inc
2024/09/2321 : 55GlobeNewswire Inc.Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian CancerNASDAQ:KRONKronos Bio Inc
2024/09/0321 : 55GlobeNewswire Inc.Kronos Bio Announces Participation in Medical and Investor Conferences in SeptemberNASDAQ:KRONKronos Bio Inc
2024/08/0905 : 15GlobeNewswire Inc.Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline UpdateNASDAQ:KRONKronos Bio Inc
2024/08/0905 : 03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
2024/07/2405 : 15GlobeNewswire Inc.Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian CancerNASDAQ:KRONKronos Bio Inc
2024/06/0506 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
2024/06/0505 : 58Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
2024/05/2406 : 15GlobeNewswire Inc.Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:KRONKronos Bio Inc
2024/05/2305 : 30GlobeNewswire Inc.Kronos Bio to Participate in Three Upcoming Healthcare Conferences and EventsNASDAQ:KRONKronos Bio Inc
2024/05/2205 : 15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRONKronos Bio Inc
2024/05/2121 : 20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
2024/05/2121 : 15GlobeNewswire Inc.Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer NASDAQ:KRONKronos Bio Inc
2024/05/1005 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
2024/05/1005 : 08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
2024/05/1005 : 05GlobeNewswire Inc.Kronos Bio Reports First-Quarter 2024 Financial ResultsNASDAQ:KRONKronos Bio Inc
2024/04/2505 : 01GlobeNewswire Inc.Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:KRONKronos Bio Inc
 Showing the most relevant articles for your search:NASDAQ:KRON

最近閲覧した銘柄

COIN
DOGEUSD
Dogecoin
USOTC
BNPQY
BNP Paribas (QX)
USOTC
RHHBY
Roche (QX)
NYSE
VZ
Verizon Communications
NYSE
JPM
JP Morgan Chase
COIN
ETHUSD
Ethereum
AMEX
XLE
Energy Select Sector SPDR
NYSE
DIS
Walt Disney
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MCD
McDonalds
CCOM
SILVER
SILVER
SPI
SP500
S&P 500
FX
USDEUR
US Dollar vs Euro
USOTC
BASFY
BASF (QX)
NYSE
CVX
Chevron
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有